The 2023 International PCOS Guideline criteria revises the Rotterdam criteria and now recommends diagnosis in adults to be based on the presence of 2 of 3 features: oligo/amenorrhea, clinical/biochemical hyperandrogenism, and polycystic ovary morphology (PCOM) on ultrasound or elevated anti-Müllerian hormone (AMH). The gene discussed is AMH; the disease is polycystic ovary syndrome.